{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:17:18Z","timestamp":1761920238899},"reference-count":65,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>Progressive multifocal leukoencephalopathy (PML) has been associated with the use of a number of multiple sclerosis (MS) immunomodulatory therapies and has assumed a critical place in the evaluation of their benefit\/risk. In this review, we discuss the European Union regulatory approach to drug\u2010induced PML in MS, highlight a number of key issues related to the current knowledge on PML, and outline possible paths to help progress the risk management of patients with MS at risk of PML.<\/jats:p>","DOI":"10.1002\/cpt.604","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T21:34:34Z","timestamp":1482356074000},"page":"283-289","source":"Crossref","is-referenced-by-count":21,"title":["Drug\u2010induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective"],"prefix":"10.1111","volume":"102","author":[{"given":"R","family":"Anton","sequence":"first","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Haas","sequence":"additional","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Arlett","sequence":"additional","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Weise","sequence":"additional","affiliation":[{"name":"Federal Institute for Drugs and Medical Devices Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Balabanov","sequence":"additional","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Mazzaglia","sequence":"additional","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Prieto","sequence":"additional","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Keller\u2010Stanislawski","sequence":"additional","affiliation":[{"name":"Department of Safety of Medicinal Products and Medical Devices Paul\u2010Ehrlich Institute, Federal Institute for Vaccines and Biomedicines Langen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Raine","sequence":"additional","affiliation":[{"name":"Medicines and Healthcare Products Regulatory Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,23]]},"reference":[{"key":"e_1_2_6_1_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/967581"},{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615602832"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2010.09.005"},{"key":"e_1_2_6_4_1","unstructured":"European Medicines Agency.Transatlantic workshop on drug\u2010related progressive multifocal leukoenchephalopathy (PML): workshop proceedings.<http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2011\/09\/WC500111562.pdf> (2011). Accessed 9 December 2016."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302478"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.S30.001","article-title":"Longitudinal stability of anti\u2010JC virus antibody status in multiple sclerosis patients: results of STRATIFY\u20101 (S30.001)","volume":"80","author":"Plavina T.","year":"2013","journal-title":"Neurology"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.02.002"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2013.10.004"},{"key":"e_1_2_6_12_1","first-page":"117","article-title":"Stratification and monitoring of natalizumab\u2010associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan C.","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.157"},{"key":"e_1_2_6_14_1","unstructured":"European Medicines Agency.Tysabri \u2013 product information. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000603\/WC500044686.pdf>. Accessed 9 December2016."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.199"},{"key":"e_1_2_6_16_1","unstructured":"European Medicines Agency.Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/10\/news_detail_002423.jsp&mid=WC0b01ac058004d5c1>. Accessed 23 October2015."},{"key":"e_1_2_6_17_1","unstructured":"European Medicines Agency.New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya. <http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/12\/news_detail_002447.jsp&mid=WC0b01ac058004d5c1>. Accessed 18 December2015."},{"key":"e_1_2_6_18_1","unstructured":"European Medicines Agency.Tysabri \u2013 European Public Assessment Report \u2013 Procedure under Article 20 of Regulation (EC) No 726\/2004 resulting from pharmacovigilance data.<http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Assessment_Report_\u2010_Variation\/human\/000603\/WC500206117.pdf> (2016). Accessed 9 December 2016."},{"key":"e_1_2_6_19_1","unstructured":"European Medicines Agency.Tysabri \u2013 European Public Assessment Report: CHMP extension of indication variation assessment report.<http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Assessment_Report_\u2010_Variation\/human\/000603\/WC500212660.pdf> (2016). Accessed 9 December 2016."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064313"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76629"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2010.09.004"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02252-13"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-014-0272-4"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2012.00484.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-014-0278-y"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03221-13"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir198"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02565-14"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00159"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-014-0294-y"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-012-0080-7"},{"key":"e_1_2_6_33_1","unstructured":"European Medicines Agency.Gilenya \u2013 product information.<http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002202\/WC500104528.pdf> (2016). Accessed 26 June 2016."},{"key":"e_1_2_6_34_1","unstructured":"European Medicines Agency.Tecfidera \u2013 product information.<http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002601\/WC500162069.pdf> (2016). Accessed 9 December 2016."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.05.003"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217315596994"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.04.004"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00216"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.114"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.07.054"},{"key":"e_1_2_6_41_1","first-page":"807","article-title":"JC virus antibody index in natalizumab\u2010treated patients: correlations with John Cunningham virus DNA and C\u2010reactive protein level","volume":"10","author":"Lanzillo R.","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00131-13"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004084"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515607651"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0365-x"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.06.008"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-158"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514534513"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24345"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-012-9366-z"},{"key":"e_1_2_6_51_1","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7071.1","article-title":"Progressive multifocal leukoencephalopathy","volume":"4","author":"Adang L.","year":"2015","journal-title":"F1000Res."},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.092353"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-08"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab1720"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0440-8"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03714-14"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.825"},{"key":"e_1_2_6_58_1","unstructured":"European Medicines Agency.Public summary of opinion on orphan designation: recombinant human interleukin\u20107 for the treatment of progressive multifocal leukoencephalopathy.<http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2012\/07\/WC500130303.pdf> (2012). Accessed 9 December 2016."},{"key":"e_1_2_6_59_1","unstructured":"Food and Drug Administration.Imatinib mesylate \u2013 orphan drug designation.<https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=428914> (2014). Accessed 9 December 2016."},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136046"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac8691"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu682"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514528760"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.15.65"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000235"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T10:29:35Z","timestamp":1718965775000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,23]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1002\/cpt.604"],"URL":"https:\/\/doi.org\/10.1002\/cpt.604","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,23]]}}}